Mon, Jul 28, 2014, 4:44 AM EDT - U.S. Markets open in 4 hrs 46 mins


% | $
Click the to save as a favorite.

ZIOPHARM Oncology, Inc. Message Board

  • markak1515 markak1515 Jan 29, 2010 11:49 AM Flag

    "The bottom line"

    from the R&R report:

    We view the results of the randomized Phase II PICASSO trial of palifosfamide in soft tissue sarcoma as very promising and as clear evidence of an active compound, and we believe that Ziopharm will attract a large partner interested in developing the compound, which could lead to the acquisition of the company. In addition, both darinaparsin and indibulin are promising, albeit earlystage, compounds, and their development is guided from among the leading physicians in the lymphoma and breast cancer space.

3.16-0.10(-3.07%)Jul 25 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Puma Biotechnology, Inc.
NYSEFri, Jul 25, 2014 4:01 PM EDT Inc.
NasdaqGSFri, Jul 25, 2014 3:59 PM EDT